InsiderTrades

Form 4 for ENTA ENANTA PHARMACEUTICALS INC

Accepted 2024-07-15 00:00:00 ET · period of report 2024-07-11 · accession 0001062993-24-013820 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
DM 2024-07-15 2024-07-11+ ENTA Rottinghaus Scott T. Chief Medical Off S - Sale+OE $15.97 -11.9K 21.7K -35% -$190.7K
D 2024-07-15 2024-07-15 ENTA Rottinghaus Scott T. Chief Medical Off M - OptEx $8.99 +5,375 27.1K +25% +$48.3K
D 2024-07-15 2024-07-15 ENTA Rottinghaus Scott T. Chief Medical Off M - OptEx $0.00 -5,375 80.6K -6% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2024-07-11 S D 4,299 $15.07 23,988 D — — (F2) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.155, inclusive.
2 Common Common Stock 2024-07-12 S D 2,271 $15.04 21,717 D — — (F3) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.16, inclusive.
3 Common Common Stock 2024-07-15 S D 5,375 $17.08 21,717 D — — (F4) The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $17.00 to $17.21, inclusive.
4 Common Common Stock 2024-07-15 M A 5,375 $8.99 27,092 D — —
5 Derivative Stock Option (Right to Buy) 2024-07-15 M D 5,375 $0.00 80,625 D $8.99 · — to 2033-11-22 5,375 Common Stock (F5) The option, representing a right to purchase a total of 86,000 shares, became or will become exercisable (subject to the optionholder's continued employment) quarterly in substantially equal installments (any fractional shares to be cumulated and to become exercisable at the end of the earliest succeeding quarterly period in which a whole share equivalent is accumulated) over four years from the date of grant (November 22, 2023).